zombie-sf-photo-200px.gifPatents generally have a fixed lifetime, but some can linger on like zombies, thanks to clever lawyering that extends their life unnaturally.

Zombies’ cost to the healthcare system can be significant. Genentech’s Cabilly patent, for instance, should have expired in 2006, but instead stands to cost buyers of antibody drugs $1 billion or more over the next decade. We have the skinny over at VentureBeat Life Sciences.


VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform
  • networking features, and more
Become a member